SLC25A17 and prostate carcinoma: Another report shows that SLC25A17 plays an essential role in the development of enzalutamide resistance which is used for the treatment of advanced-stage prostate cancer, and SLC25A17 may be identified as a therapeutic target to circumvent drug resistance [19].